胸腺五肽联合左氧氟沙星治疗复治菌阳性肺结核的效果及对PCThs CRP和T淋巴细胞亚群的影响.docxVIP

胸腺五肽联合左氧氟沙星治疗复治菌阳性肺结核的效果及对PCThs CRP和T淋巴细胞亚群的影响 胸腺五肽联合左氧氟沙星治疗复治菌阳性肺结核的效果及对pct、hs-crp和t淋巴细胞亚群的影响 　　【摘要】目的：探讨胸腺五肽联合左氧氟沙星治疗复治菌阳性肺结核的效果及对pct、hs-crp和t淋巴细胞亚群的影响。方法：选取笔者所在科室2017年1月-2018年7月收治的复治菌阳性肺结核患者82例，按照入院先后顺序均分为分析组和对照组。对照组给予常规治疗联合左氧氟沙星胶囊，分析组在对照组基础上配合胸腺五肽，比较两组治疗前后pct、hs-crp和t淋巴细胞亚群变化情况及临床疗效。结果：治疗后分析组病灶吸收率、痰菌转阴率、空洞闭合缩小率及临床症状改善率均明显高于对照组，差异均有统计学意义（p0.05）;治疗后两组pct、hs-crp、cd3+、cd4+及cd4+/cd8+均较治疗前改善，且分析组改善幅度明显优于对照组，差异均有统计学意义（p0.05）。結论：给予复治菌阳性肺结核患者胸腺五肽配合左氧氟沙星治疗，可提高临床效果，缓解炎症症状，增强免疫力，有助于身体恢复，值得在临床上推广应用。 　　【关键词】胸腺五肽左氧氟沙星复治菌阳性肺结核 　　[abstract]objective：toinvestigatetheefficacyofthymopentincombinedwithlevofloxacinintreatingre-treatedbacteriologicalpositivepulmonarytuberculosisandtheeffectonpct，hs-crpandtlymphocytesubsets.method：atotalof82patientswithre-treatedbacteriologicalpositivepulmonarytuberculosisadmittedtoourdepartmentfromjanuary2017tojuly2018wereenrolled.thepatientsweredividedintotheanalysisgroupandthecontrolgroupaccordingtotheorderofadmission.thecontrolgroupreceivedroutinetreatmentcombinedwithlevofloxacincapsules，andtheanalysisgroupreceivedthymopentinonthebasisofthecontrolgroup.thechangesofpct，hs-crpandtlymphocytesubsetsbeforeandaftertreatmentandclinicaleffectwerecomparedbetweenthetwogroups.result：aftertreatment，lesionabsorptionrate，sputumnegativeconversionrate，cavityclosurereductionrateandclinicalsymptomimprovementrateintheanalysisgroupweresignificantlyhigherthanthoseofthecontrolgroup，andthedifferenceswerestatisticallysignificant（p0.05）.aftertreatment，pct，hs-crp，cd3+，cd4+andcd4+/cd8+improvedinbothgroupscomparedwithbeforetreatment，andtheimprovementoftheanalysisgroupweresignificantlybetterthanthoseofthecontrolgroup，andthedifferenceswerestatisticallysignificant（p0.05）.conclusion：thymopentincombinedwithlevofloxacininpatientswithre-treatedbacteriologicalpositivepulmonarytuberculosiscanimproveclinicalefficacy，alleviateinflammationsymptoms，enhanceimmunityandhelpthebodyrecover.itisworthyofclinicalapplication. 　　复治菌阳性肺结核（re-treatedbacteriologicalpositivepulmonar